North American Travelan® sales up 98% in the first half of FY20
January 28 2020 - 8:30AM
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the treatment of gut mediated diseases,
today announced the sales results of its commercially available and
over-the-counter gastrointestinal and digestive health supplement
Travelan® for the first half of fiscal year 2020 ending on December
31, 2019.
Immuron experienced robust gross sales growth in
the US, Canada and Australia throughout the first half of FY20,
with global sales reaching AU $1.68M* during the 6-month
period.
North America sales of Travelan® were up 98% YoY
for the first half of FY20, spurred on by the launch of Travelan®
in Canadian pharmacies in June 2019 and also by robust growth in
online Amazon sales within the US. Passport Health, the USA’s
largest travel medicine provider, also contributed to the strong
result, with Travelan® sales rising by 27% within the Passport
Health network of clinics. A series of podcasts on the “Not old,
better” network assisted in raising consumer awareness of Travelan®
in the US.
In Australia, Immuron sales reached AU $954K*
for the first half FY20, displaying a 33% YoY growth rate.
Travelan® strengthened its presence in Australian pharmacies with
in-store promotional material and TV advertising with Chemist
Warehouse. Immuron’s participation in Medical Practitioner
conferences also contributed to increased awareness of Travelan®
within the medical community.
“The sales momentum for Travelan® which was
already evident during the first quarter of fiscal year 2020 has
continued unabated throughout the first half of fiscal year 2020 as
consumer awareness of Travelan® continues to grow,” said Dr. Gary
S. Jacob, CEO of Immuron Ltd. “As we step through the second half
of this fiscal year we will continue to focus on increasing
consumer awareness of the brand, particularly in North American
markets, as we look to expand the market for this important health
care product. At the same time, we are seeking FDA registration for
Travelan® as a drug to prevent travelers’ diarrhea which we believe
will provide a further boost to our sales potential moving
forward.”
*Unaudited gross revenue
COMPANY CONTACT:
Gary S. Jacob, Ph.D.Chief Executive OfficerPh: +61
(0)3 9824 5254info@immuron.com |
AUS INVESTOR RELATIONS:
Peter TaylorNWR CommunicationsPh: +61 (0)4 1203
6231peter@nwrcommunications.com.au |
USA INVESTOR RELATIONS:
Dave Gentry - CEO RedChip Companies, Inc. US Ph:
+1 (407) 491 4498 dave@redchip.com |
About
Travelan®Travelan® is an orally administered
passive immunotherapy that prophylactically reduces the likelihood
of contracting travelers’ diarrhea. Travelan® is a highly purified
tabletized preparation of hyper immune bovine antibodies and other
factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with
travelers’ diarrhea. In Australia, Travelan® is a listed medicine
on the Australian Register for Therapeutic Goods (AUST L 106709)
and is indicated to reduce the risk of Travelers’ Diarrhea, reduce
the risk of minor gastro-intestinal disorders and is antimicrobial.
In Canada, Travelan® is a licensed natural health product (NPN
80046016) and is indicated to reduce the risk of Travelers’
Diarrhea. In the U.S., Travelan® is sold as a dietary supplement
for digestive tract protection.
About Travelers’
diarrheaTravelers’ diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and
occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases,
with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a
significant proportion of cases. The more serious infections with
Salmonella spp. the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers’ diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel and safe
technology platform with one commercial asset generating revenue.
In Australia, Travelan® is a listed medicine on the Australian
Register of Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travellers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licenced natural health product (NPN 80046016) and
is indicated to reduce the risk of Travellers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection in accordance with section 403 (r)(6) of the Federal
Drug Administration (FDA). Immuron’s lead clinical candidate,
IMM-124E, is presently in Phase II trials in Severe Alcoholic
Hepatitis (SAH) and Pediatric Nonalcoholic Fatty Liver Disease
(NAFLD). The company now has plans to develop a U.S. registration
dossier for IMM-124E for Travellers’ Diarrhea. Immuron’s second
clinical-stage asset, IMM-529, targets Clostridium difficile
Infections (CDI), and is in clinical trial development in CDI
patients. These products together with the Company’s other
preclinical immunotherapy pipeline products currently under
development targeting immune-related and infectious diseases are
anticipated to meet pressing needs in the global immunotherapy
market. For more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited
to, any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024